FdaApplication
NDA 208114
Identifiers
- fda_app_no: NDA208114
Properties
| Property | Value |
|---|---|
| applicant_name | JAZZ PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2016-03-30 |
Revenue by product
DEFITELIO
| Period | Revenue |
|---|---|
| Q2 2026 | $62.0M |
| Q1 2026 | $47.4M |
| Q4 2025 | $58.9M |
| Q3 2025 | $51.8M |
| Q2 2025 | $48.1M |
| Q1 2025 | $40.7M |
| Q4 2024 | $57.6M |
| Q3 2024 | $65.8M |
| Q2 2024 | $45.4M |
| Q1 2024 | $47.7M |
| Q4 2023 | $51.1M |
| Q3 2023 | $47.7M |
| Q2 2023 | $46.1M |
| Q1 2023 | $39.1M |
| Q4 2022 | $40.7M |
| Q3 2022 | $49.5M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| DEFITELIO | DEFIBROTIDE SODIUM | 200MG/2.5ML (80MG/ML) | SOLUTION;INTRAVENOUS |
1 product